202 studies found for:    Open Studies | "Triplets"
Show Display Options
Rank Status Study
21 Not yet recruiting Capecitabine + BKM120 TNBC BC Brain Met
Conditions: Triple Negative Breast Cancer;   Brain Metastases;   Breast Cancer
Interventions: Drug: BKM120;   Drug: capecitabine
22 Recruiting AZD8186 First Time In Patient Ascending Dose Study
Conditions: Advanced Castrate-resistant Prostate Cancer (CRPC);;   Squamous Non-Small Cell Lung Cancer (sqNSCLC);;   Triple Negative Breast Cancer (TNBC)
Intervention: Drug: AZD8186
23 Recruiting Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB Over-expressing Cancer.
Condition: Metastatic GPNMB Over-expressing Triple Negative Breast Cancer.
Interventions: Drug: CDX-011;   Drug: Capecitabine
24 Recruiting Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Bevacizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carbo/cyclo;   Drug: Carbo/cyclo + bevacizumab;   Drug: Paclitaxel;   Drug: Paclitaxel + Bevacizumab
25 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
26 Recruiting Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Veliparib
27 Recruiting X-chromosome Inactivation, Epigenetics and the Transcriptome
Conditions: Turner Syndrome;   Klinefelter Syndrome;   Triple X Syndrome;   47 XYY Syndrome;   Aortic Aneurysm
Intervention:
28 Recruiting An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Conditions: Malignant Solid Tumour;   Ovarian Cancer;   Triple Negative Breast Cancer;   Advanced Melanoma;   B-cell Malignancy, Low-grade
Interventions: Drug: E7449 alone;   Drug: E7449 plus TMZ;   Drug: E7449 plus carboplatin and paclitaxel
29 Recruiting Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent
Conditions: Solid Tumors;   Triple Negative Breast Cancer;   Non Small Cell Lung Cancer;   Colorectal Cancer;   ER/PR Positive Breast Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Gastric Cancer;   Gastro-Esophageal Junction Adenocarcinoma;   Head and Neck Cancer
Intervention: Drug: Ferumoxytol followed by MM-398
30 Recruiting A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Conditions: Melanoma;   Breast Neoplasms;   Lobular Carcinoma;   Triple-negative Breast Cancer;   Pancreatic Adenocarcinoma;   Colorectal Cancer;   Head and Neck Cancer;   Other Tumor Types With Documented Genetic Alterations Upstream in the Wnt Signaling Pathway
Intervention: Drug: LGK974
31 Recruiting Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Conditions: Dose Escalation;   Safety;   Preliminary Efficacy;   Advanced Solid Tumors;   Metastatic Breast Cancer;   Advanced Pancreatic Adenocarcinoma;   Metastatic Colorectal Cancer;   Recurrent Glioblastoma Multiforme;   Gastric Cancer;   Gastroesophageal Junction Cancer;   Triple Negative Metastatic Breast Cancer;   Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer
Interventions: Drug: LDE225;   Drug: BKM120
32 Recruiting eMet CAR RNA T Cells Targeting Breast Cancer
Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Biological: cMet RNA CAR T cells
33 Recruiting Triple Negative Breast Cancer: Study of Molecular and Genetic Factors
Condition: Breast Cancer
Intervention: Genetic: BRCA1 BRCA2 PTEN PALB2 mutation
34 Recruiting BKM120 For Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: BKM120
35 Recruiting Cabozantinib for Metastatic Triple Negative BrCa
Condition: Breast Cancer
Intervention: Drug: XL184
36 Unknown  Modified Triple Osteotomy for Acetabular Dysplasia
Conditions: Sharp Angle;   Center Edge Angle;   Femoral Head Extrusion Index;   Center Head Distance Discrepancy
Intervention:
37 Recruiting Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Metformin;   Drug: Erlotinib
38 Recruiting Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel, Capecitabine;   Drug: Doxorubicin, cyclophosphamide;   Drug: Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
39 Recruiting Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212
Condition: Breast Cancer
Intervention: Drug: GSK1120212
40 Recruiting Cisplatin + RT for Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy;   Drug: Cisplatin

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years